The Vanguard Group 13D and 13G filings for Sage Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-31 09:55 am Sale | 2024-12-31 | 13G | Sage Therapeutics, Inc. SAGE | The Vanguard Group | 4,838,169 7.900% | -922,280 (-16.01%) | Filing |
| 2024-11-12 4:56 pm Unchanged | 2024-09-30 | 13G | Sage Therapeutics, Inc. SAGE | The Vanguard Group | 5,760,449 9.430% | 0 (Unchanged) | Filing |
| 2024-11-04 3:28 pm Unchanged | 2024-09-30 | 13G | Sage Therapeutics, Inc. SAGE | The Vanguard Group | 5,760,449 9.430% | 0 (Unchanged) | Filing |
| 2024-11-04 2:10 pm Sale | 2024-09-30 | 13G | Sage Therapeutics, Inc. SAGE | The Vanguard Group | 5,760,449 9.430% | -542,098 (-8.60%) | Filing |
| 2024-06-10 12:15 pm Purchase | 2024-05-31 | 13G | Sage Therapeutics, Inc. SAGE | The Vanguard Group | 6,302,547 10.470% | 983,187 (+18.48%) | Filing |
| 2024-02-13 5:13 pm Purchase | 2023-12-29 | 13G | Sage Therapeutics, Inc. SAGE | The Vanguard Group | 5,319,360 8.860% | 433,808 (+8.88%) | Filing |
| 2023-02-09 11:32 am Purchase | 2022-12-30 | 13G | Sage Therapeutics, Inc. SAGE | The Vanguard Group | 4,885,552 8.210% | 307,311 (+6.71%) | Filing |
| 2022-02-10 08:37 am Sale | 2021-12-31 | 13G | Sage Therapeutics, Inc. SAGE | The Vanguard Group | 4,578,241 7.770% | -20,874 (-0.45%) | Filing |
| 2021-02-10 11:47 am Sale | 2020-12-31 | 13G | Sage Therapeutics, Inc. SAGE | The Vanguard Group | 4,599,115 8.840% | -91,667 (-1.95%) | Filing |